The Surface, Issue #7 is now available! This month we feature five recent publications with high clinical relevance for Canadian dermatologists. The Surface was emailed to all PSOLVE+ members on Tues, Sep 28 and can be read online here.

The Surface Issue #7, October 2021 edition, was sent to all PSOLVE+ members by email on Tuesday, Sep 28, and can be accessed online here. This edition covers:

  • Concomitant PsA and PsO results from the EXCEED study
  • Risk of drug exposure in PsO patients on COVID-19 outcomes in France
  • Treatment of PsO and the natural history of PsA
  • PASI-HD – a solution for BSA <10%
  • Survey on the potential impact of a biomarker patch in PsO treatment selection

To view all issues of The Surface, go to psolve.org/the-surface

Dr. Michael Cecchini presents highlights from the American Academy of Dermatology (AAD) Virtual Meeting Experience 2021 [Video 12 min]

— Français ci-dessous —

This video series was developed by a faculty of Canadian dermatologists from across Canada as part of the C2 Dermatology: Connect & Collaborate learning program, under the supervision of Dr. Simon Nigen and Dr. Vimal Prajapati. View all AAD C2 Dermatology videos at psolve.org/c2-derm.

In this Video #4, Dr. Michael Cecchini from Richmond Hill, Ontario, presents a 12-minute video update from the 2021 AAD VMX.


>> View the video [12 min]

Video is in English with French subtitles.

Topics reviewed in this video include:

  • What new options are emerging in the treatment landscape for psoriasis?
  • How should we manage biologic therapies in patients with psoriasis and obesity?
  • Are the current treatment approaches for pediatric psoriasis patients sufficient?
  • Can children with psoriasis be safely treated with biologic therapies? 

In compliance with Innovative Medicines Canada, this program is for Healthcare Professionals only, and is supported by Novartis Pharmaceuticals Canada.


Vous êtes convié(e)s à visionner les Modules vidéos de microapprentissage extraits du programme C2 Dermatology (Connect & Collaborate) Proceedings de l’American Academy of Dermatology Association Virtual Meeting Experience 2021 sous la supervision de Simon Nigen, MD, FRCPC (Montréal, QC) et de Vimal H. Prajapati, MD, FRCPC, FAAD (Calgary, AB). Au cours des prochaines semaines, nous mettrons en ligne les différents Modules selon le calendrier joint: psolve.org/c2-derm

Dans cette vidéo n° 4, le Dr Michael Cecchini (Richmond Hill, Ontario) présente un résumé de sessions tirées du congrès virtuel de l’AAD 2021.

>> Voir la vidéo [12 min]

* Vidéo en anglais avec sous-titres français.

Les sujets de cette vidéo incluent :

  • Quelles sont les nouvelles options émergentes dans le cadre de traitements du psoriasis?
  • Comment adapter les thérapies biologiques chez les patients atteints de psoriasis et d’obésité?
  • Les approches thérapeutiques actuelles pour les patients atteints de psoriasis pédiatrique sont-elles suffisantes?
  • L’utilisation d’un traitement biologique pour traiter les enfants atteints de psoriasis est-elle sécuritaire? 

En conformité avec Médicaments novateurs Canada, ce programme est réservé aux professionnels de la santé et est parrainé par Novartis Pharma Canada.

Dr. Toni Burbidge presents highlights from the American Academy of Dermatology (AAD) Virtual Meeting Experience 2021 [Video 17 min]

— Français ci-dessous —

This video series was developed by a faculty of Canadian dermatologists from across Canada as part of the C2 Dermatology: Connect & Collaborate learning program, under the supervision of Dr. Simon Nigen and Dr. Vimal Prajapati. View all AAD C2 Dermatology videos at psolve.org/c2-derm.

In this Video #3, Dr. Toni Burbidge from Calgary, Alberta, presents a 17-minute video update from the 2021 AAD VMX.


>> View the video [17 min]

Video is in English with French subtitles.

Topics reviewed in this video include:

  • Does the mechanism of action of drugs targeting the IL-23 or IL-17A pathway explain differences in their clinical efficacy?
  • What are the cardiovascular benefits of biologic therapies vs.non-biologic therapies?
  • What guidance is there about the management of psoriatic disease?
  • How do you select psoriasis therapies in a complex landscape? 

In compliance with Innovative Medicines Canada, this program is for Healthcare Professionals only, and is supported by Novartis Pharmaceuticals Canada.


Vous êtes convié(e)s à visionner les Modules vidéos de microapprentissage extraits du programme C2 Dermatology (Connect & Collaborate) Proceedings de l’American Academy of Dermatology Association Virtual Meeting Experience 2021 sous la supervision de Simon Nigen, MD, FRCPC (Montréal, QC) et de Vimal H. Prajapati, MD, FRCPC, FAAD (Calgary, AB). Au cours des prochaines semaines, nous mettrons en ligne les différents Modules selon le calendrier joint: psolve.org/c2-derm

Dans cette vidéo n° 3, la Dre Toni Burbidge (Calgary, Alberta) présente un résumé de sessions tirées du congrès virtuel de l’AAD 2021.

>> Voir la vidéo [17 min]

* Vidéo en anglais avec sous-titres français.

Les sujets de cette vidéo incluent :

  • Le mécanisme d’action des médicaments ciblant la voie de l’IL-23 ou de l’IL-17A explique-t-il leur efficacité  clinique différente? 
  • Quels sont les avantages cardiovasculaires des traitements biologiques comparativement aux traitements  non biologiques? 
  • Quelles sont les directives concernant la gestion du psoriasis? 
  • Comment choisir un traitement biologique dans un cadre aussi complexe? 

En conformité avec Médicaments novateurs Canada, ce programme est réservé aux professionnels de la santé et est parrainé par Novartis Pharma Canada.

Dr. Lawrence Haiducu presents highlights from the American Academy of Dermatology (AAD) Virtual Meeting Experience 2021 [Video 8 min]

— Français ci-dessous —

This video series was developed by a faculty of Canadian dermatologists from across Canada as part of the C2 Dermatology: Connect & Collaborate learning program, under the supervision of Dr. Simon Nigen and Dr. Vimal Prajapati. View all AAD C2 Dermatology videos at psolve.org/c2-derm.

In this Video #2, Dr. Lawrence Haiducu from Maple Ridge, BC, presents an 8-minute video update from the 2021 AAD VMX.

>> View the video [7 min, 58 seconds]

* Video is in English with French subtitles.

Topics reviewed in this video include:

  • Should we consider biologic therapies for the treatment of mild-to-moderate psoriasis?
  • How do we manage psoriatic disease in the context of comorbidities or COVID? 
  • What is the impact of patient-reported outcomes on treatment selection in psoriatic disease?
  • What evidence is there to guide our selection of a biologic therapy in difficult-to-treat areas? 

In compliance with Innovative Medicines Canada, this program is for Healthcare Professionals only, and is supported by Novartis Pharmaceuticals Canada.


Vous êtes convié(e)s à visionner les Modules vidéos de microapprentissage extraits du programme C2 Dermatology (Connect & Collaborate) Proceedings de l’American Academy of Dermatology Association Virtual Meeting Experience 2021 sous la supervision de Simon Nigen, MD, FRCPC (Montréal, QC) et de Vimal H. Prajapati, MD, FRCPC, FAAD (Calgary, AB). Au cours des prochaines semaines, nous mettrons en ligne les différents Modules selon le calendrier joint: psolve.org/c2-derm

Dans cette vidéo n° 2, le Dr Lawrence Haiducu (Maple Ridge, BC) présente un résumé de sessions tirées du congrès virtuel de l’AAD 2021.

>> Voir la vidéo [7 min, 58 secondes]

* Vidéo en anglais avec sous-titres français.

Les sujets de cette vidéo incluent :

  • Faut-il envisager les thérapies biologiques pour traiter le psoriasis léger ou modéré? 
  • Comment traiter le psoriasis en contexte de comorbidités et de COVID?
  • Quelle est l’incidence des résultats rapportés par les patients sur le choix du traitement pour le  psoriasis?
  • Quelles données probantes orientent le choix d’un traitement biologique pour les zones difficiles à  traiter? 

En conformité avec Médicaments novateurs Canada, ce programme est réservé aux professionnels de la santé et est parrainé par Novartis Pharma Canada.

Dr. Farheen Mussani presents highlights from the American Academy of Dermatology (AAD) Virtual Meeting Experience 2021 [Video 9 min]

— Français ci-dessous —

This video series was developed by a faculty of Canadian dermatologists from across Canada as part of the C2 Dermatology: Connect & Collaborate learning program, under the supervision of Dr. Simon Nigen and Dr. Vimal Prajapati. View all AAD C2 Dermatology videos at psolve.org/c2-derm.

In this Video #1, Dr. Farheen Mussani from Stoney Creek, Ontario, presents a 9-minute video update from the 2021 American Academy of Dermatology (AAD) Virtual Meeting Experience.


>> View the video [9 min, 26 seconds]

Video is in English with French subtitles.

Topics reviewed in this video include:

  • Why should we pay attention to the burden of disease in all patients?
  • What treatment regimen to consider in the management of palmoplantar psoriasis?
  • What does real-world data mean for your practice?
  • Why should we discuss the patient’s perspective around ‘remission’?

In compliance with Innovative Medicines Canada, this program is for Healthcare Professionals only, and is supported by Novartis Pharmaceuticals Canada.


Vous êtes convié(e)s à visionner les Modules vidéos de microapprentissage extraits du programme C2 Dermatology (Connect & Collaborate) Proceedings de l’American Academy of Dermatology Association Virtual Meeting Experience 2021 sous la supervision de Simon Nigen, MD, FRCPC (Montréal, QC) et de Vimal H. Prajapati, MD, FRCPC, FAAD (Calgary, AB). Au cours des prochaines semaines, nous mettrons en ligne les différents Modules selon le calendrier joint: psolve.org/c2-derm

Dans cette vidéo n° 1, le  Dre Farheen Mussani (Stoney Creek, ON) présente une vidéo de 9 minutes de l’AAD VMX 2021.

>> Voir la vidéo [9 min, 26 secondes]

* Vidéo en anglais avec sous-titres français.

Les sujets de cette vidéo incluent :

  • Pourquoi devrions-nous nous préoccuper du fardeau de la maladie pour tous les patients?
  • Quel régime de traitement doit-on envisager pour les patients atteints de psoriasis palmoplantaire?
  • Que signifient les données du monde réel pour votre pratique?
  • Pourquoi devrions-nous tenir compte de la perspective du patient concernant la rémission?

En conformité avec Médicaments novateurs Canada, ce programme est réservé aux professionnels de la santé et est parrainé par Novartis Pharma Canada.

The Surface, Issue #6 is now available! This month we feature publications on predictors of response and drug survival, and systematic reviews of rare cutaneous disorders. The Surface was emailed to all PSOLVE+ members on Mon, Aug 2 and can be read online here.

The Surface Issue #6, August 2021 edition, was sent to all PSOLVE+ members by email on Monday, August 2, and can be accessed online here. This edition covers:

  • Predictors of methotrexate discontinuation in plaque psoriasis
  • Systematic review of predictive biomarkers for treatment response in psoriasis and psoriatic arthritis
  • Normalization of bone microarchitecture following anti-TNF treatment for PsA
  • Characterizing Degos disease by systematic review
  • Case report of cutaneous Emmonsia infection in a renal transplant recipient
  • Case report of atypical melanocytic nevi with segmental distribution

To view all issues of The Surface, go to psolve.org/the-surface

The Surface, Issue #5 is now available, highlighting 5 new articles clinically relevant for Canadian dermatologists. The Surface was emailed to all PSOLVE+ members on Mon, Jul 5 and can be read online here.

The Surface Issue #5, July 2021 edition, was sent to all PSOLVE+ members by email on Monday, July 5, and can be accessed online here. This edition covers:

  • Upadacitinib for biologic-refractory psoriatic arthritis
  • Urticaria disease activity during and after pregnancy
  • Case reports of paradoxical sarcoidosis in patients on anti-TNFs
  • Fixed drug eruption following two different antibiotics
  • Local hyperthermia treatment for cervical HPV

To view all issues of The Surface, go to psolve.org/the-surface

The Surface, Issue #4 is now available, this month highlighting 6 new articles clinically relevant for Canadian dermatologists. The Surface was emailed to all PSOLVE+ members on Tues, Jun 1 and can be read online here.

The Surface Issue #4, June edition, was sent to all PSOLVE+ members by email on Tuesday, June 1, and can be accessed online here. This edition covers:

  • Safety and efficacy of secukinumab in a single, 300mg/2mL pre-filled syringe
  • Risk of malignancy with up to five years of secukinumab treatment
  • Reviewing the evidence for over-the-counter supplements in dermatology
  • Telogen effluvium patient demographics during the pandemic
  • North American Contact Dermatitis Group patch testing with sodium disulfite
  • Hereditary angioedema in the emergency department

To view all issues of The Surface, go to psolve.org/the-surface

The Surface, Issue #3 is now available, this month highlighting 4 new articles clinically relevant for Canadian dermatologists. The Surface was emailed to all PSOLVE+ members on Tues, May 4 and can be read online here.

The Surface Issue #3, May edition, was sent to all PSOLVE+ members by email on Tuesday, May 4, and can be accessed online here. This edition covers:

  • Considerations for use of SARS-CoV-2 vaccines in psoriasis patients
  • Retrospective analysis of oral methotrexate for alopecia areata
  • Case series and literature review of pleural effusion in PsA patients
  • Polymorphisms associated with methotrexate treatment outcomes

To view all issues of The Surface, go to psolve.org/the-surface

The Surface, Issue #2 is now available! Check out this month’s summaries of recent publications with high clinical relevance to Canadian dermatologists.

The Surface Issue #2, April edition, was sent to all PSOLVE+ members by email on Monday, March 29, and can be accessed online here. This edition covers:

  • Vaccine literacy amongst patients with psoriasis
  • Pregnancy outcomes from the PSOLAR registry
  • Bimekizumab phase 3 results in moderate-to-severe plaque psoriasis
  • Targeting the IL-23/IL-17 pathway in plaque psoriasis
  • Compassionately addressing teratogenic risk factors in the transgender population
  • Real-world safety profile of acitretin in psoriasis patients

To view all issues of The Surface, go to https://psolve.org/the-surface/